Business
Elicio Therapeutics Reports 2024 Financial Results and Provides Corporate Updates
Completed enrollment of Phase 2 AMPLIFY-7P randomized study; disease-free survival (“DFS”) event-driven interim analysis expected in Q3 2025 Aligned with U.S. Food and Drug Administration (“FDA”) on key elements of planned ELI-002 Phase 3 study design, including dose, patient population and primary endpoint analysis Strengthened cash position to support operations beyond the anticipated AMPLIFY-7P Phase 2 interim analysis BOSTON, March 31, 2025 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (Nasd
About this update from Elicio Therapeutics, Inc.
[{"type":"image","alt":"Elicio Therapeutics Inc.","displaySize":"","headline":null,"caption":"Elicio Therapeutics Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":108,"url":"https://media.zenfs.com/en/globenewswire.com/cce9a5a17e9aa5fb6eff6b1fd10e2995"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/dHRdNHTDYzkn3cTM5JZhnw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE1MTtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/cce9a5a17e9aa5fb6eff6b1fd10e2995","width":300,"height":108}},"lazy":false},{"type":"text","content":"Completed enrollment of Phase 2 AMPLIFY-7P randomized study; disease-free survival (“DFS”) event-driven interim analysis expected in Q3 2025","length":140,"tagName":"p"},{"type":"text","content":"Aligned with U.S. Food and Drug Administration (“FDA”) on key elements of planned ELI-002 Phase 3 study design, including dose, patient population and primary endpoint analysis","length":176,"tagName":"p"},{"type":"text","content":"Strengthened cash position to support operations beyond the anticipated AMPLIFY-7P Phase 2 interim analysis","length":107,"tagName":"p"},{"type":"text","content":"BOSTON, March 31, 2025 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (Nasdaq: ELTX, “Elicio Therapeutics” or “Elicio”), a clinical-stage biotechnology company developing a pipeline of novel immunotherapies for the treatment of cancer, today reported financial results for the year ending December 31, 2024 and provided recent corporate and clinical updates.","length":367,"tagName":"p"},{"type":"text","content":"“We made substantial progress in 2024 advancing our cancer immunotherapy pipeline and achieving major milestones, including completing enrollment in our first randomized Phase 2 clinical trial. We believe that ELI-002 could play a transformational role in preventing the recurrence of difficult-to-treat KRAS-mutant cancers,” said Robert Connelly, Chief Executive Officer of Elicio. “During the fourth quarter, we presented highly encouraging ELI-002 Phase 1a data at major medical meetings. Across two monotherapy trials that enrolled a total of 39 patients, we observed strong concordance between T cell response and anti-tumor activity—with antigen spreading beyond KRAS to other personalized tumor neo-antigens. Data presented at the Society for Immunotherapy of Cancer (“SITC”) 2024 Annual Meeting and the Europ...